U.S. Interleukin Market Size, Share & Forecast 2026–2032

ID: MR-11641 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: U.S. Interleukin Market (interleukin-targeting biologics, drug substance and finished products)
  • ✓Market Size 2024: US$48 billion
  • ✓Market Size 2032: US$82 billion
  • ✓CAGR: 7.2%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Biosimilar Erosion Reshapes Value: Ustekinumab biosimilars from Amgen and Samsung Bioepis entered US pharmacies in 2025, eroding Johnson & Johnson's Stelara volumes faster than payer models assumed. Value growth now concentrates in IL-23 and IL-17 franchises held by AbbVie and Novartis.
FINDING 02
Dupixent Growth Ceiling Emerging: Consensus expects Regeneron and Sanofi's Dupixent to keep compounding in US atopic dermatitis indefinitely. New-start prescriptions are beginning to shift toward Galderma's IL-31 blocker Nemluvio. Dupixent's US growth will plateau before 2030 as biologic-naive patients split across targets.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Onshore Fill-Finish Capacity: Procurement and investment teams should lock multi-year supply agreements for IL-23 and IL-17 drug substance with US-based fill-finish capacity before the fourth quarter of 2026, because Section 232 pharmaceutical tariff exposure remains unresolved and onshoring commitments are tightening.

The United States' Role in the Global Interleukin Supply Chain

The United States is the world's largest consumer of interleukin-targeting biologics, yet its supply chain role is weighted toward finishing and bulk manufacturing rather than raw material production. Domestic drug substance output is concentrated at Amgen's Juncos, Puerto Rico and Holly Springs, North Carolina operations and Fujifilm Diosynth's Holly Springs campus. Finished biologics from Ireland, Switzerland and Germany account for a large share of imports, with Ireland supplying substantial immunology volumes into US distribution.

Import dependency is highest for upstream bioprocess inputs. Single-use bioreactor components, cell culture media and chromatography resins draw heavily on German and Singaporean suppliers, while peptide intermediates arrive from China and India. Net exports flow in the opposite direction for finished monoclonal antibodies bound for Canada and Japan. The result is a country that captures high value at the end of the chain but imports much of its manufacturing foundation.

Growth Drivers for U.S. Interleukin Production and Trade

Onshoring commitments are the most material driver of production capacity. Eli Lilly, Johnson & Johnson and AbbVie have announced multibillion-dollar US manufacturing investments since 2025, adding bioreactor capacity that reduces reliance on Irish and Swiss fill-finish sites. This shifts the import mix from finished vials toward bulk drug substance, which carries lower tariff exposure and raises domestic value capture. Expansion also lifts demand for domestic single-use equipment and cold-chain freight.

Pipeline expansion is the second driver. Next-generation IL-23, IL-17 and IL-4/13 agents are moving into pediatric and additional indications, sustaining volume growth through specialty distribution networks. Biosimilar competition for IL-12/23 volumes pushes originators toward lower manufacturing cost structures, increasing contract demand for domestic CDMO capacity in North Carolina and New Jersey. Import substitution follows as companies bring peptide and reagent sourcing onshore.

Supply Chain Risks and Trade Barriers in U.S. Interleukin Supply

Bioprocess inputs remain concentrated among a small number of suppliers. Single-use bioreactor film, cell culture media components and specialized chromatography resins are sourced largely from Germany and Singapore, creating single-point failure risk. Any disruption to Sartorius or Merck KGaA shipments would delay US drug substance release by months, because qualification of alternative materials requires lengthy regulatory filings and validation runs.

Trade policy creates the second exposure. Section 232 pharmaceutical tariffs and reciprocal tariff frameworks with the EU, Japan and Switzerland introduce uncertainty for finished biologic imports, particularly for products invoiced in euros and Swiss francs. Transatlantic air cargo lanes face capacity constraints during peak seasons, and temperature-controlled freight costs rise when lanes tighten. Currency volatility compresses margins for importers whose revenues are denominated in dollars but whose contracts are priced in foreign currency.

Trade and Investment Opportunities in U.S. Interleukin Manufacturing

Bulk drug substance capacity for IL-23 and IL-17 antibodies is underbuilt relative to demand, creating an opening for contract manufacturers. Lonza's Portsmouth, New Hampshire site and Fujifilm's Holly Springs campus are natural candidates for expansion contracts with originators. Investors should target mid-scale single-use facilities in North Carolina and New Jersey, where skilled biopharma labor and FDA inspection proximity align with customer demand.

Import substitution for peptide intermediates and cytokine reagents is commercially viable. Domestic producers of GMP-grade interleukin proteins could serve US biotech clients currently sourcing from China and India. Logistics hub development at Memphis, Tennessee, which hosts major air cargo operations, could support temperature-controlled biologics distribution to Canada and Latin America, linking domestic manufacturing to regional export flows.

Market at a Glance

MetricValue
Market Size 2024US$48 billion
Market Size 2032US$82 billion
Growth Rate (CAGR)7.2%
Most Critical Decision FactorSecure onshore bulk drug substance capacity ahead of tariff changes
Largest RegionNortheast and Mid-Atlantic corridor
Competitive StructureOligopolistic, led by five multinational originators

Leading Market Participants

  • AbbVie
  • Johnson & Johnson
  • Novartis
  • Eli Lilly
  • Regeneron Pharmaceuticals
  • Sanofi
  • Amgen
  • Genentech
  • UCB
  • GSK

Regulatory and Trade Policy Affecting U.S. Interleukin Imports and Exports

The US trade framework for biologics combines bilateral tariff arrangements with sector-specific measures. The 2025 US-EU framework set a 15% ceiling on most European goods, and comparable arrangements cover Japan and Switzerland. USMCA governs trade with Canada and Mexico but carries limited direct relevance to finished biologics. The Section 232 pharmaceutical investigation remains the most consequential open policy lever for interleukin imports.

Investment and pricing policy shape the market equally. Medicare drug price negotiation selected Stelara for initial pricing, accelerating biosimilar substitution in IL-12/23 volumes. FDA cGMP inspection requirements and biologics license approvals govern every import and domestic production site, while foreign trade zones allow bonded storage of drug substance awaiting tariff clarity. Proposed BIOSECURE restrictions on certain foreign biotech suppliers add further scrutiny to supplier selection.

U.S. Interleukin Supply Chain Outlook to 2032

The supply chain will shift from importing finished interleukin products toward domestic bulk drug substance production through 2032. Puerto Rico and North Carolina will anchor this expansion, while Ireland and Switzerland retain specialized fill-finish roles for European-licensed products. Freight flows will reorient toward domestic distribution hubs, reducing exposure to transatlantic lane disruption.

Technology will alter comparative advantage. Continuous bioprocessing and AI-driven process analytics reduce batch cycle times, favoring facilities that can adopt these systems quickly. Bispecific antibodies and next-generation interleukin modulators will require new upstream inputs, so suppliers of specialized media and resins that localize production in the United States will capture disproportionate share of incremental demand.

Frequently Asked Questions

Ireland, Switzerland and Germany account for the largest shares of finished biologic imports. Ireland's immunology volumes are particularly significant for US distribution.
Section 232 tariffs could raise landed costs for finished biologics imported without US-based fill-finish. Companies with domestic drug substance capacity face the lowest exposure.
Transatlantic air cargo capacity and peak-season lane tightness create the most frequent delays. Temperature-controlled freight costs rise sharply when these lanes constrain.
Amgen's Puerto Rico and North Carolina sites and Fujifilm's Holly Springs campus lead current expansion. Lonza's Portsmouth, New Hampshire site is also a candidate for contract capacity growth.
Single-use bioreactor film, media and chromatography resins come from a concentrated group of suppliers in Germany and Singapore. Qualifying alternatives requires lengthy regulatory validation, so disruptions delay drug substance release for months.

Market Segmentation

By Interleukin Target
  • IL-23
  • IL-17
  • IL-4 and IL-13
  • IL-6
  • IL-12 and IL-23
By Indication
  • Plaque Psoriasis
  • Atopic Dermatitis
  • Rheumatoid Arthritis
  • Severe Asthma
  • Inflammatory Bowel Disease
By Distribution Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Interleukin Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Interleukin Target Insights
4.1 IL-23
4.2 IL-17
4.3 IL-4 and IL-13
4.4 IL-6
4.5 Others
Chapter 05 Indication Insights
5.1 Plaque Psoriasis
5.2 Atopic Dermatitis
5.3 Rheumatoid Arthritis
5.4 Severe Asthma
5.5 Others
Chapter 06 Distribution Channel Insights
6.1 Hospital Pharmacies
6.2 Specialty Pharmacies
6.3 Retail Pharmacies
6.4 Mail-Order Pharmacies
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 AbbVie
7.2.2 Johnson & Johnson
7.2.3 Novartis
7.2.4 Eli Lilly
7.2.5 Regeneron Pharmaceuticals
7.2.6 Sanofi
7.2.7 Amgen
7.2.8 Genentech
7.2.9 UCB
7.2.10 GSK
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.